Track topics on Twitter Track topics that are important to you
Pulmocide has raised €28.25M ($30.4M) in Series B that will let the company progress its candidates for respiratory infections through early clinical trials. Pulmocide, based in London, is developing inhaled drugs to treat respiratory syncytial virus (RSV) and Aspergillus infections in ...
This awesome article Top Investors Back British Biotech’s Series B to Fight Pulmonary Infections appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)NEXT ARTICLE
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...